Company Description
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.
In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP.
The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.
Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Country | United States |
| Founded | 2004 |
| IPO Date | May 2, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Todd Brady |
Contact Details
Address: 131 Hartwell Avenue, Suite 320 Lexington, Massachusetts 02421 United States | |
| Phone | 781 761 4904 |
| Website | aldeyra.com |
Stock Details
| Ticker Symbol | ALDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001341235 |
| CUSIP Number | 01438T106 |
| ISIN Number | US01438T1060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Todd C. Brady M.D., Ph.D. | Chief Executive Officer, President and Director |
| Michael Alfieri | Head of Finance and Principal Financial and Accounting Officer |
| Dr. Stephen G. Machatha Ph.D. | Chief Development Officer |
| David Burke | Head of Investor Relations |
| Laura Nichols | Operations Manager |
| Dr. Adam Lazorchak | Director of Translational Sciences and Non-Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Dec 31, 2025 | 8-K | Current Report |
| Dec 16, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 5, 2025 | 10-Q | Quarterly Report |
| Oct 28, 2025 | 8-K | Current Report |
| Aug 19, 2025 | 8-K | Current Report |